Homeostatic control of uridine and the role of uridine phosphorylase: A biological and clinical update

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1587, Issue 2-3, 2002, Pages 133-144

  Pizzorno, Giuseppe ^a   Cao, Deliang ^a   Leffert, Janine J ^a   Russell, Rosalind L ^a   Zhang, Dekai ^a   Handschumacher, Robert E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Fluorouracil; Cytoskeleton; p53; Pyrimidine; Uridine; Uridine phosphorylase

Indexed keywords

2',3',5' TRI O ACETYLURIDINE; CREATINE KINASE; CYCLIC GMP; DOXORUBICIN; FILAMIN; FLUOROPYRIMIDINE; FLUOROURACIL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; METHOTREXATE; PLECTIN; PN 401; PROTEIN KINASE C; PROTEIN P53; SPARFOSIC ACID; UNCLASSIFIED DRUG; URACIL; URIDINE; URIDINE DERIVATIVE; URIDINE PHOSPHORYLASE; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; CELL TRANSPORT; CLINICAL TRIAL; CYTOSKELETON; CYTOTOXICITY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED DISEASE; ENZYME ACTIVITY; EVALUATION; GASTROINTESTINAL TOXICITY; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, P53; HOMEOSTASIS; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); SUBCELLULAR FRACTIONS; URIDINE; URIDINE PHOSPHORYLASE; VIMENTIN;

EID: 0037130273     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(02)00076-5     Document Type: Review

References (145)

1. Salvage of circulating pyrimidine nucleosides in the rat
2. Hereditary orotic aciduria: Long-term therapy with uridine and a trial of uracil
3. Clinical and pharmacological studies of Benzylacyclouridine, a uridine phosphorylase inhibitor
4. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity
5. Physiological concentrations of purines and pyrimidines
6. Novel single pass exchange of circulating uridine in rat liver
7. Discrete roles of hepatocytes and nonparenchymal cells in uridine catabolism as a component of its homeostasis
8. Uridine and its nucleotides: Biological actions, therapeutic potentials
9. Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides
10. Uridine, xanthine, and urate contents in human seminal plasma
11. Sperm motility and interactions among seminal uridine, xanthine, urate, and ATPase in fertile and infertile men
12. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency
13. Pyrimidines and CNS regulation
14. Developmental disorder associated with increased cellular nucleotidase activity
15. Pyrimidine derivatives: Their psychotropic properties and the molecular mechanisms of their central action
16. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity
17. N3-phenacyluridine, a novel hypnotic compound, interacts with the benzodiazepine receptor
18. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites
19. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity
20. Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data
21. Effect of uridine supply on glycogen resynthesis after ischaemia in the isolated perfused rat heart
22. Cytidine and uridine requirement of the brain
23. Cerebral endogenous substrate utilization during the recovery period after profound hypoglycemia
24. Effects of uridine in the treatment of diabetic neuropathy: An electrophysiological study
25. Specificity of mouse uridine phosphorylase. Chromatography, purification and properties
26. Pyrimidine nucleosidases, their classification and relationship to uric acid ribonucleoside phosphorylase
27. Pyrimidine acyclonucleosides inhibitors of uridine phosphorylase
28. 5-Benzylacyclouridine and 5-benzyloxybenzylacycloruridine, potent inhibitors of uridine posphorylase
29. Uridine and deoxyuridine phosphorylase from Ehrlich ascites tumor
30. Variant uridine phosphorolytic activity in human breast and head-neck tumors: A potential target for improving 5-FU therapy
31. Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity
32. Uridine phosphorylase molecular properties and mechanism of catalysis
33. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine
34. Synthesis of 5-benzyl and 5-benzyloxybenzyl 2,2′-anhydrouridines and related nucleoside analogs as inhibitors of uridine phosphorylase
35. Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver
36. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine
37. Studies of fluorinated pyrimidines: XVIII. The degradation of 5-fluoro-2′-deoxyuridine and related compounds by nucleoside phosphorylase
38. Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2′-deoxyuridine
39. Role of uridine phosphorylase for antitumor activity in 5′-deoxy-5-fluorouridine
40. Potentiation of 5-fluoro-2′-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine
41. Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5-deoxy-5-fluoruridine
42. Purification, cloning, and expression of murine uridine phosphorylase
43. Cloning and expression of human uridine phosphorylase
44. Regulation of expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in human colon carcinoma cells
45. Activation and cytotoxicity of 5′-deoxy-5-fluorouridine in c-H-ras transformed NIH 3T3 cells
46. Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice
47. Species differences in substrate specificity of pyrimidine nucleoside phosphorylase
48. Effects of N,N-dimethylformamide and sodium butyrate on enzymes of pyrimidine metabolism in cultures human tumor cells
49. High dose 5-fluorouracil with delayed uridine "rescue" in mice
50. Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases
51. Potentiation of 5-fluoro-2′-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine
52. Tissue uridine pools evidence in vivo of a concentrative mechanism for uridine uptake
53. Expression, characterization and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors
54. Fluorouracil: Biochemistry and pharmacology
55. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine
56. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells
57. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation
58. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin
59. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue
60. Phase I clinical trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer
61. Mediated transport of nucleosides in human erythrocytes. Accelerative exchange diffusion of uridine and thymidine and specificity toward pyrimidine nucleosides as permeants
62. Mediated transport of nucleosides by human erythrocytes. Specificity toward purine nucleosides as permeants
63. Nucleoside translocation in sheep reticulocytes and fetal erythrocytes: A proposed model for the nucleoside transporter
64. Thymidine transport in cultured mammalian cells. Kinetic analysis, temperature dependence and specificity of the transport system
65. Inhibitors of nucleoside transport as probes and drugs
66. Nitrobenzylthioinosine-insensitive uridine transport in human lymphoblastoid and murine leukemia cells
67. Heterogeneity of nucleoside transport in mammalian cells. Two types of transport activity in L1210 and other cultured neoplastic cells
68. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rent1 and rent2) from rat tissues
69. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line
70. Renal handling of 2′-deoxyadenosine and adenosine in humans and mice
71. Renal transport of 2′-deoxytubercidin in mice
72. Uphill transport of pyrimidine nucleosides in renal brush border vesicles
73. +-dependent uridine transport in rat renal brush border membrane vesicles
74. Adenosine transport in perfused rat kidney and renal cortical membrane vesicles
75. Active transport of nucleosides and nucleoside drugs
76. Uridine uptake by isolated intestinal epithelial cells of guinea pig
77. Sodium-dependent nucleoside transport in mouse leukemia L1210 cells
78. Sodium-dependent nucleoside transport in rabbit intestinal epithelium
79. Sodium-dependent nucleoside co-transport in brush-border membranes from rabbit ileum
80. Sodium-dependent nucleoside transport in mouse epithelial cells. Two transport systems with differing substrate specificities
81. +-nucleoside co-transporter (hCNT1)
82. +-nucleoside transporter in Xenopus laevis oocytes
83. +-dependent nucleoside transport systems of rat intestine in isolated oocytes of Xenopus laevis. Demonstration that rat jejunum expresses the purine-selective system N1 (cif) and a second, novel system N3 having broad specificity for purine and pyrimidine nucleosides
84. Nucleoside transport in brush border membrane vesicles from human kidney
85. Inhibitor-sensitive, sodium-linked transport of nucleoside analogs in leukemia cells from patients
86. Genomic structure, chromosomal mapping and promoter region sequence of murine Uridine Phosphorylase Gene
87. P53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction
88. Uridine phosphorylase association with vimentin: Intracellular distribution and localization
89. Angiogenic factor
90. Thymidine phosphorylase is angiogenic and promotes tumor growth
91. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor
92. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers
93. Pyrimidine nucleotide metabolism in human colon carcinomas: Comparison of normal tissues, primary tumors and xenografts
94. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
95. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis
96. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma
97. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer
98. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up regulated in breast cancer epithelium and endothelium
99. Angiogenic activity of enzymes
100. Relationship between gene expression level of phosphorylating enzymes for 5-FU and chemosensitivity by drug response assay in human colorectal carcinoma
101. Inhibition of thymidine phosphorylase by 6-amino-thymine and derivatives of 6-amino-uracil
102. Expression of uridine and thymidine phosphorylase genes in human breast carcinoma
103. A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer
104. Molecular aspects of heavy-chain class switching
105. Recombination at the human alpha-globulin gene cluster: Sequence features and topological constraints
106. Hybrid survival motor neuron genes in patients with autosomal recessive spinal muscular atrophy: New insights into molecular mechanisms responsible for the disease
107. Organization and chromosomal localization of the human platelet-derived endothelial cell growth factor gene
108. GATA-binding transcription factors in hematopoietic cells
109. Roles of gastric GATA DNA-binding proteins
110. Structure of IRF-1 with bound DNA reveals determinants of interferon regulation
111. Interferon regulatory factor-1 induces the expression of the interferon-stimulated genes
112. Myc target genes
113. Isolation and analysis of cellular DNA fragments directly binding to c-Myc protein
114. Accelerated proliferative senescence of rat embryo fibroblasts after stable transfection of multiple copies of the c-Myc DNA-binding sequence
115. Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: Implications for regulation
116. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding
117. Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc
118. Definition of a consensus binding site for p53
119. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage
120. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
121. The p53 tumor suppressor: Critical regulator of life and death in cancer
122. Intermediate filaments and cytoplasmic networking: New connections and more functions
123. Recent insights into the assembly, dynamics, and function of intermediate filament networks
124. Intermediate filament dynamics
125. Vimentin: The conundrum of the intermediate filament gene family
126. The function of intermediate filaments in cell shape and cytoskeletal integrity
127. Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (vimentin) scaffold
128. Association of the beta isoform of protein kinase C with vimentin filaments
129. Cyclic guanosine monophosphate-dependent protein kinase is targeted to intermediate filaments and phosphorylates vimentin in A23187-stimulated human neutrophils
130. Immunocytochemical localization of protein kinases Yes and Src in amoeboid microglia in culture: Association of Yes kinase with vimentin intermediate filaments
131. Copurification of Vimentin, energy metabolism enzymes, and a MER5 homolog with nucleoside diphosphate kinase
132. A putative protein-sequestration site involving intermediate filaments for protein degradation by autophagy. Studies with microinjected purified glycolytic enzymes in 3T3-L1 cells
133. Association of creatine phosphokinase with the cytoskeleton of cultured mammalian cells
134. Cytoskeletal association of the A and B nucleoside diphosphate kinases of interphasic but not mitotic human carcinoma cell lines: Specific nuclear localization of the B subunit
135. Plectin sidearms mediate interaction of intermediate filaments with microtubules and other components of the cytoskeleton
136. Distribution and ultrastructure of plectin arrays in subclones of rat glioma C6 cells differing in intermediate filament protein (vimentin) expression
137. A 300,000-mol-wt intermediate filament-associated protein in baby hamster kidney (BHK-21) cells
138. Identification of the intermediate filament-associated protein gyronemin as filamin. Implications for a novel mechanism of cytoskeletal interaction
139. Potential signalling roles for UTP and UDP: Sources, regulation and release of uracil nucleotides
140. The role and regulation of adenosine in the central nervous system
141. Adenosine and cardioprotection during ischaemia and reperfusion: An overview
142. Adenosine receptors and their ligands
143. Uridine receptor: Discovery and its involvement in sleep mechanism
144. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder